Common sense investment opportunities around the world

Weekly newsletter (free)

In-depth research reports (from USD 49 p.a.)

100% ChatGPT-free

Expand your thinking by tapping Into my 30+ years of global investment research expertise

Discover world-class companies trading at low prices

Support your own idea generation and research

Benefit from an independent view of the world

Undervalued-Shares.com in 13 minutes

Discover my investment ideas

"Swen Lorenz’s research service on international stocks might provide the best value of any service out there."

Michael Fritzell, Asian Century Stocks

MOST POPULAR

Free weekly dispatches

Join my free weekly column to gain access to my investment insights - and my FREE eBook "Weird Shit Investing 2024 - The Manual".

Name(Required)
Name(Required)
This field is for validation purposes and should be left unchanged.

Latest Reports for Members

Actinium-225, aka "the world's rarest drug"

10 October 2024

If a single gram of Actinium-225 was available, it would fetch in the double-digit millions.

The trouble is, hardly anyone has got any of it.

This uber-rare radioactive isotope has turned out a potent weapon to treat cancer. The head of oncology at Novartis believes it could become "a mainstream therapy" for tackling the "big traditional cancers". That's 50 (!) different forms of cancers.

Commonly referred to as Ac-225, the material delivers a cannonball punch to cancer cells, but without affecting neighbouring healthy cells.

Big Pharma is pouring billions into new pharmaceuticals using Ac-225.

One little-known Western European company has suddenly emerged as the potential global market leader for supplying the material that is at the heart of it all.

Internet leader at a bargain price

4x from a deal with Ukraine?

Wind energy – turnaround ahead?

Laggard turning growth stock

What members say

|

Your work rate is simply outstanding! I also admire your ability to put your politics aside and invest as you see it.

Guy D., Australia

|

Swen Lorenz is offering one of the world's cheapest investor clubs. For just $50 per year (or €4 per month), you get more value than from any investor magazine. There are certainly other specialised investment newsletters that are similarly fascinating and successful, but these usually cost 10-20 times more!

Andreas Lambrou, emerging market specialist and publisher, Germany

|

This Membership is the best investment in your own stock market future. Anyone looking for an experienced opportunity finder will find what they need with Swen Lorenz!

Moritz H., Germany

|

I count Swen up there with Jim Rogers and Doug Casey & The Wandering Investor as inspirations for my global investing career.

Marvin L., USA

|

Gotta say that @uv_shares is one of my favorite blogs. We are paid up subscribers. Always some quirky stock I haven’t heard of. Recommend you follow…

Kuppy, AdventuresInCapitalism

|

I just wanted to praise you for the work you are presenting us and for the way your write your reports (clean, understandable, easy to consume, and focused on long term value - and not short term propaganda).

Tiago M., Portugal

|

I am a Lifetime subscriber to your newsletter. It is one of the best, if not the best out there in this space.

Hung-Wah C., Hong Kong

|

You are the Sherlock Holmes of the stock market. Love your analysis. It's not only pretty accurate but fun to read.

Pablo, Argentina

|

Your unique, nonconformist approach to investing and life is second to none and those who are following you are always benefiting on multiple levels. Who would have thought that there are still huge treasure chests waiting to be dug out, not with the shovels and pickaxes of the past but with curiosity, wisdom, persistence and diligence?

Andreas S., Austria

As seen in

Most recent

Latest reports (for Members only)

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.

Internet leader at a bargain price

Internet leader at a bargain price

If you missed buying Meta or Spotify in 2022, this global Internet leader is for you. One major investor is already on the case.
4x from a deal with Ukraine?

4x from a deal with Ukraine?

If or when Russian securities become fungible again, this stock could move quite quickly – as, indeed, it has already started to do.